Fig. 1.

Proportion of efficacy outcome responders* for ACQ-5 score, SGRQ total score, pre-bronchodilator FEV₁, and exacerbations. *Responders were defined as: ACQ-5 score improvement from baseline of ≥ 0.5-points at Week 32; SGRQ total score improvement from baseline of ≥ 4 points at Week 32; pre-bronchodilator FEV₁ improvement from baseline of ≥ 100 mL at Week 32; ≥ 50% reduction in the annualised rate of clinically significant exacerbations during the study treatment period versus the previous year; patients who discontinued mepolizumab treatment but remained within the study (n = 2) were considered non-responders in this analysis. ACQ-5 Asthma Control Questionnaire-5, FEV₁ forced expiratory volume in 1s, SGRQ St George’s Respiratory Questionnaire